{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-002707","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2022-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.383278+00:00","generated_at":"2026-06-27T07:50:23.051981+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M","bullets":["Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).","Q4 GAAP net income $32.1M (vs $26M); FY GAAP net income $112.5M (vs $106M). Non-GAAP Q4 $42.6M.","2022 revenue guidance $400-430M, implying 9-17% growth.","Repurchased 10M shares for $207.5M in Q4; cash+investments $335.8M.","Clinical: ovarian cancer Phase 3 start Q2 2022; AIWG Phase 2 data Q4 2022; NDA for Cushing's Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-002707","json":"https://secwatch.observer/filing/0001628280-22-002707.json","markdown":"https://secwatch.observer/filing/0001628280-22-002707.md","text":"https://secwatch.observer/filing/0001628280-22-002707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/0001628280-22-002707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/cort-20220215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:50:23.051981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}